Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010 May 20; 28(15):2598-603.